Kurma Partners

Kurma Partners is a prominent European venture capital firm based in Paris, France, dedicated to financing innovation within the healthcare and biotechnology sectors. Established with a clear focus on life sciences, the firm targets companies developing novel therapeutics, diagnostics, medical devices, and digital health solutions. Their investment strategy spans early-stage and growth-stage opportunities, aiming to support the translation of scientific breakthroughs into tangible patient benefits.

The firm manages several funds, demonstrating a significant commitment to the life sciences ecosystem. A key milestone was the closing of Kurma Biofund IV in 2022, which successfully raised €250 million, exceeding its initial target. This fund, alongside previous vehicles like Kurma Biofund III (€160 million), contributes to Kurma Partners' substantial assets under management, which now exceed €500 million. This financial scale enables them to provide robust support to their portfolio companies.

Kurma Partners typically engages as a lead or co-lead investor, often participating in syndicates with other specialized venture capital firms. Their initial investment checks generally range from €3 million to €10 million, providing crucial early capital for promising ventures. Beyond the initial investment, the firm is prepared to commit significant follow-on funding, potentially investing up to €20 million per company over its lifecycle, underscoring their long-term partnership approach. They actively support their portfolio companies through strategic guidance, network access, and operational expertise, aiming to accelerate their development and market entry.

With a portfolio that includes over 50 companies since its inception, Kurma Partners has played a vital role in fostering innovation across Europe's biotech landscape. Their investments have contributed to the development of numerous therapies and technologies, addressing unmet medical needs. The firm's deep scientific and industry expertise allows them to identify and nurture high-potential ventures, solidifying their reputation as a key player in European life sciences venture capital.